PSIX heads into tonight's earnings print riding an 18.6% weekly surge — yet carrying enough short interest and a fresh short-score jump to keep the debate alive.
Options positioning is the most striking signal heading into the release. Call demand has overwhelmed puts to a degree rarely seen over the past year: the put/call ratio has collapsed to 0.27, just above its 52-week low of 0.272, and running roughly 1.3 standard deviations below its 20-day average of 0.35. That means options buyers have been piling into upside exposure, not hedging. The PCR has essentially halved from levels above 0.58 in late June — a decisive shift in sentiment over six weeks. Borrow availability is relatively comfortable at 174%, meaning the lending pool is not under stress, and borrowing costs remain low at 0.57% despite a 43% rise over the week — still not the kind of level that signals a squeeze is imminent.
Short interest complicates the bullish read. At 7.3% of the free float, short positioning is meaningful — nearly 1.68 million shares — though the week-on-week trend has been friendly to the bulls, with SI down almost 8% over the past week as shorts covered into the rally. The ORTEX short score has moved in the other direction: it jumped from 60.1 to 65.4 between July 31 and August 5, a five-point climb that puts it in the most bearish 5th percentile of its sector universe on this metric. That divergence — covering shorts alongside a rising short score — suggests the remaining bears are more convicted even as some have stepped aside. Days to cover stand at 3.9, so any sharp upside move could still create meaningful pressure on the holdouts.
The analyst picture offers upside optionality, but with important caveats. The consensus is nominally "buy" with two buy ratings and one hold, and a mean price target that implies substantial distance above the current $33.02 price. However, the most recent analyst action — from Freedom Broker in May — was a downgrade to Hold alongside a steep target cut from $107 to $66, following an earlier cut at Jefferies from $110 to $93. Both firms have been walking targets lower since initiating coverage in late 2025. Given the stock has since retreated further to the low $30s, the $70 consensus target is stale and the gap between where analysts sit and where the stock trades reflects genuine uncertainty. The valuation is not obviously demanding — a trailing PE near 9.3x and EV/EBITDA near 7.4x — but those multiples have been compressing over the past month alongside the stock's 10% pullback. Institutional interest has been building: Point72 entered with a 5% stake in Q1, and Yunqi Capital and Dimensional Fund Advisors both added shares recently, lending some credibility to the bull case on valuation.
The earnings print — delayed and rescheduled multiple times before landing tonight — will test whether PSIX's operational momentum justifies the options market's burst of optimism, or whether the short sellers who remain positioned at 7.3% of the float have correctly read something the call buyers have not.
See the live data behind this article on ORTEX.
Open PSIX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
